SVRA
Savara Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-43/100
Last price
4.65
▼ 0.13 (2.72%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
4.78
Day high
4.83
Day low
4.60
Volume
2.29M
Market cap
$955.39M
P/E (TTM)
—
52W range
3.34 – 7.01
Trailing performance
Returnvs SPY
1W
-8.46%
-10.4%
1M
-13.41%
-14.6%
3M
-27.12%
-31.6%
6M
-19.55%
-37.7%
YTD
-22.89%
-37.1%
1Y
+33.24%
+16.8%
3Y
+23.02%
-59.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on SVRA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+220.66K
Net buying
Buy transactions
2
615.19K shares
Sell transactions
1
394.53K shares
Net transactions
+3
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
6.49M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 15, 26 | LUTZ ROBERT MATTHEW Chief Operating Officer |
STOCK | 35.00K | $0 | Direct |
| Jun 22, 26 | LOWRANCE DAVID L. CPA Chief Financial Officer |
SELL | 394.53K | $2.24M | Direct |
| Jun 22, 26 | LOWRANCE DAVID L. CPA Chief Financial Officer |
CONVERSION | 580.19K | $1.02M | Direct |
| Mar 18, 26 | LOWRANCE DAVID L. CPA Chief Financial Officer |
CONVERSION | 366.75K | $588.46K | Direct |
| Feb 13, 26 | MCCRACKEN JOSEPH S Director |
CONVERSION | 1.81K | $3.18K | Direct |
| Dec 16, 25 | LOWRANCE DAVID L. CPA Chief Financial Officer |
STOCK | 32.00K | $0 | Direct |
| Dec 16, 25 | PAULS MATTHEW Chief Executive Officer |
STOCK | 129.00K | $0 | Direct |
| Dec 10, 25 | PAULS MATTHEW Chief Executive Officer |
STOCK | 23.63K | $0 | Direct |
| Dec 9, 25 | ELAM NEVAN C Director |
STOCK | 40.00K | $0 | Direct |
| Dec 9, 25 | MCCRACKEN JOSEPH S Director |
STOCK | 40.00K | $0 | Direct |
| Dec 9, 25 | VAN ES-JOHANSSON AN Director |
STOCK | 40.00K | $0 | Direct |
| Dec 9, 25 | HAWKINS RICHARD JAMES Director |
STOCK | 40.00K | $0 | Direct |
| Dec 2, 25 | ELAM NEVAN C Director |
CONVERSION | 5.86K | $8.56K | Direct |
| Nov 14, 25 | HAWKINS RICHARD JAMES Director |
CONVERSION | 5.86K | $8.56K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ELAM NEVAN C |
Director | 106.89K | Stock Award(Grant) |
ERICKSON ANNE |
Officer | 434.67K | Stock Award(Grant) |
HAWKINS RICHARD JAMES |
Director | 161.33K | Stock Award(Grant) |
LOWRANCE DAVID L. CPA |
Chief Financial Officer | 536.03K | Sale |
LUTZ ROBERT MATTHEW |
Chief Operating Officer | 328.98K | Stock Award(Grant) |
MCCRACKEN JOSEPH S |
Director | 302.64K | Conversion of Exercise of derivative security |
PARKER BRADEN |
Officer | 105.00K | Stock Award(Grant) |
PAULS MATTHEW |
Chief Executive Officer | 1.19M | Stock Gift |
PRATT RAYMOND DENNIS M.D. |
Officer | 340.05K | Stock Award(Grant) |
VAN ES-JOHANSSON AN |
Director | 102.50K | Stock Award(Grant) |
Fundamentals
Market cap$955.39M
Enterprise value$1.04B
Revenue (TTM)—
Gross profit$-86.84M
EBITDA$-142.70M
Net income$-139.31M
EPS (TTM)$-0.58
Free cash flow$-57.19M
Total cash$174.82M
Total debt$30.41M
Book value / share$0.57
Shares outstanding205.46M
Float129.75M
Short % of float24.66%
Dividend yield0.00%
Beta (5Y)0.20
Valuation & profitability ratios
Trailing P/E—
Forward P/E-14.90
PEG ratio—
Price / sales—
Price / book8.23
EV / revenue—
EV / EBITDA-7.27
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-105.48%
Return on assets-50.14%
Debt / equity21.17
Current ratio10.13
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $81.40M | $78.03M | $44.26M | $27.88M | +4.3% |
| Selling, general & admin | $42.06M | $25.04M | $15.67M | $10.93M | +68.0% |
| Total operating expense | $122.76M | $102.40M | $59.21M | $38.04M | +19.9% |
| Operating income | -$122.76M | -$102.40M | -$59.21M | -$38.04M | -19.9% |
| Net interest income | $4.16M | $6.47M | $4.44M | -$88.00K | -35.6% |
| Pre-tax income | -$118.84M | -$95.88M | -$54.70M | -$38.15M | -23.9% |
| Net income | -$118.84M | -$95.88M | -$54.70M | -$38.15M | -23.9% |
| Net income to common | -$118.84M | -$95.88M | -$54.70M | -$38.15M | -23.9% |
| Basic EPS | -0.53 | -0.48 | -0.33 | -0.25 | -10.4% |
| Diluted EPS | -0.53 | -0.48 | -0.33 | -0.25 | -10.4% |
| EBIT | -$122.76M | -$102.40M | -$59.21M | -$38.04M | -19.9% |
| EBITDA | -$122.68M | -$102.27M | -$59.13M | -$37.88M | -20.0% |
| Basic shares | 222.39M | 198.19M | 165.20M | 152.77M | +12.2% |
| Diluted shares | 222.39M | 198.19M | 165.20M | 152.77M | +12.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $33.18M | $15.13M | $26.59M | $52.10M | — | +119.3% |
| Cash & short-term investments | $235.70M | $196.33M | $162.32M | $125.88M | — | +20.1% |
| Total current assets | $241.62M | $202.13M | $165.95M | $128.95M | — | +19.5% |
| Property, plant & equipment | $100.00K | $165.00K | $270.00K | $51.00K | — | -39.4% |
| Total assets | $253.44M | $212.88M | $177.56M | $139.78M | — | +19.1% |
| Total current liabilities | $20.40M | $14.72M | $10.60M | $5.87M | — | +38.5% |
| Current debt | — | — | — | — | $8.33M | — |
| Long-term debt | $29.91M | $26.62M | $26.35M | $26.08M | — | +12.4% |
| Total debt | $29.91M | $26.73M | $26.49M | $26.14M | — | +11.9% |
| Total liabilities | $50.30M | $41.43M | $37.19M | $32.00M | — | +21.4% |
| Retained earnings | -$608.09M | -$489.25M | -$393.37M | -$338.67M | — | -24.3% |
| Shareholder equity | $203.13M | $171.45M | $140.37M | $107.78M | — | +18.5% |
| Working capital | $221.22M | $187.41M | $155.35M | $123.09M | — | +18.0% |
| Net tangible assets | $191.50M | $161.11M | $129.41M | $97.12M | — | +18.9% |
| Shares issued | 204.57M | 172.42M | 138.14M | 114.05M | — | +18.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$118.84M | -$95.88M | -$54.70M | -$38.15M | -23.9% |
| Depreciation & amortisation | $87.00K | $130.00K | $77.00K | $167.00K | -33.1% |
| Stock-based compensation | $14.42M | $9.86M | $4.18M | $2.04M | +46.3% |
| Change in working capital | $5.00M | $1.83M | $4.07M | $960.00K | +173.4% |
| Operating cash flow | -$101.04M | -$89.09M | -$51.06M | -$34.55M | -13.4% |
| Capital expenditure | -$22.00K | -$25.00K | -$296.00K | -$9.00K | +12.0% |
| Investing cash flow | -$18.44M | -$39.94M | -$57.12M | $52.65M | +53.8% |
| Share buybacks | -$5.14M | -$995.00K | -$1.21M | -$3.00K | -416.6% |
| Financing cash flow | $137.81M | $117.58M | $82.78M | $87.00K | +17.2% |
| Free cash flow | -$101.06M | -$89.11M | -$51.36M | -$34.56M | -13.4% |
| End cash position | $33.18M | $15.13M | $26.59M | $52.10M | +119.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $21.95M | $23.40M | $20.90M | $20.59M | $20.75M | — | -6.2% |
| Selling, general & admin | $18.99M | $15.57M | $12.53M | $9.63M | $10.65M | — | +22.0% |
| Total operating expense | $40.97M | $38.14M | $33.42M | $30.25M | $31.44M | — | +7.4% |
| Operating income | -$40.97M | -$38.14M | -$33.42M | -$30.25M | -$31.44M | — | -7.4% |
| Net interest income | $829.00K | $1.06M | $1.20M | $548.00K | $921.00K | — | -21.6% |
| Pre-tax income | -$40.23M | -$37.28M | -$32.24M | -$29.56M | -$30.40M | — | -7.9% |
| Tax provision | — | — | — | — | — | $0 | — |
| Net income | -$40.23M | -$37.28M | -$32.24M | -$29.56M | -$30.40M | — | -7.9% |
| Net income to common | -$40.23M | -$37.28M | -$32.24M | -$29.56M | -$30.40M | — | -7.9% |
| Basic EPS | -0.16 | -0.15 | — | -0.14 | -0.14 | -0.12 | -6.7% |
| Diluted EPS | -0.16 | -0.15 | — | -0.14 | -0.14 | -0.12 | -6.7% |
| EBIT | -$40.97M | -$38.14M | -$33.42M | -$30.25M | -$31.44M | — | -7.4% |
| EBITDA | -$40.87M | -$38.07M | -$33.43M | -$30.18M | -$31.37M | — | -7.3% |
| Basic shares | 253.57M | 253.28M | — | 216.46M | 216.43M | 216.15M | +0.1% |
| Diluted shares | 253.57M | 253.28M | — | 216.46M | 216.43M | 216.15M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $41.80M | $38.79M | $33.18M | $16.28M | $17.44M | +7.8% |
| Cash & short-term investments | $173.03M | $202.77M | $235.70M | $124.39M | $146.44M | -14.7% |
| Total current assets | $178.32M | $209.26M | $241.62M | $128.20M | $150.99M | -14.8% |
| Property, plant & equipment | $641.00K | $130.00K | $100.00K | $85.00K | $119.00K | +393.1% |
| Goodwill & intangibles | $11.29M | $11.36M | $11.64M | $11.65M | $11.63M | -0.7% |
| Total assets | $192.14M | $221.65M | $253.44M | $140.92M | $163.76M | -13.3% |
| Total current liabilities | $17.60M | $15.54M | $20.40M | $16.76M | $13.63M | +13.3% |
| Long-term debt | $30.11M | $30.07M | $29.91M | $29.78M | $29.65M | +0.1% |
| Total debt | $30.41M | $30.11M | $29.91M | $29.83M | $29.74M | +1.0% |
| Total liabilities | $48.48M | $45.61M | $50.30M | $46.54M | $43.28M | +6.3% |
| Retained earnings | -$685.60M | -$645.37M | -$608.09M | -$575.85M | -$546.29M | -6.2% |
| Shareholder equity | $143.66M | $176.04M | $203.13M | $94.39M | $120.48M | -18.4% |
| Working capital | $160.72M | $193.73M | $221.22M | $111.44M | $137.36M | -17.0% |
| Net tangible assets | $132.37M | $164.68M | $191.50M | $82.73M | $108.86M | -19.6% |
| Shares issued | 205.40M | 204.92M | 204.57M | 172.85M | 172.84M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$40.23M | -$37.28M | -$32.24M | -$29.56M | -$30.40M | -7.9% |
| Depreciation & amortisation | $99.00K | $66.00K | -$129.00K | $75.00K | $73.00K | +50.0% |
| Stock-based compensation | $7.76M | $10.73M | $5.36M | $3.42M | $2.67M | -27.6% |
| Change in working capital | $2.96M | -$6.14M | $2.16M | $3.83M | $2.07M | +148.2% |
| Operating cash flow | -$29.75M | -$33.05M | -$25.06M | -$22.53M | -$26.26M | +10.0% |
| Capital expenditure | -$222.00K | -$54.00K | -$2.00K | -$2.00K | -$15.00K | -311.1% |
| Investing cash flow | $32.60M | $38.78M | -$93.56M | $21.47M | $24.33M | -15.9% |
| Share buybacks | -$5.00K | -$240.00K | -$4.79M | -$24.00K | -$114.00K | +97.9% |
| Financing cash flow | $189.00K | -$195.00K | $135.56M | -$23.00K | -$49.00K | +196.9% |
| Free cash flow | -$29.97M | -$33.10M | -$25.06M | -$22.53M | -$26.28M | +9.5% |
| End cash position | $41.80M | $38.79M | $33.18M | $16.28M | $17.44M | +7.8% |
Options analytics
Put / call volume
6.88
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.00
-57.0% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
-12.5%
Calls bid over puts
Call volume
8
Contracts, this expiry
Put volume
55
Contracts, this expiry
Heaviest call OI
2.00
0 contracts
Heaviest put OI
5.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.15 | -0.16 | -9.6% |
| Mar 2026 | -0.14 | — | — |
| Dec 2025 | -0.12 | -0.13 | -11.4% |
| Sep 2025 | -0.13 | -0.14 | -6.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.16 | 5 | $0 | 0.0% |
| Next quarter | -0.15 | 5 | $2.02M | 0.0% |
| Current year | -0.62 | 5 | $2.02M | 0.0% |
| Next year | -0.31 | 5 | $81.97M | +3,963.5% |
Analyst targets & ownership
Mean target$10.94
High target$16.00
Low target$9.00
Implied upside135.22%
Analyst count8
ConsensusNONE
Strong buy / Buy2 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders2.55%
Held by institutions106.75%
Institutions holding237
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.97
-6.37% from price
SMA 20
5.15
-9.68% from price
SMA 50
5.35
-13.08% from price
SMA 100
5.43
-14.39% from price
SMA 200
5.51
-15.57% from price
EMA 12
4.99
-6.86% from price
EMA 26
5.16
-9.82% from price
EMA 50
5.29
-12.11% from price
RSI (14)
31.8
Neutral
MACD (12,26,9)
-0.16
Hist -0.05
ATR (14)
0.25
5.47% of price
Realised vol 30D
37.9%
Annualised
Bollinger upper
5.59
20, 2σ
Bollinger lower
4.71
20, 2σ
50 / 200 cross
Death
5.35 vs 5.51
Trend bias
Below 200
-15.57%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.30
More volatile than market
Correlation to SPY
0.31
Loosely linked
Realised vol 30D
37.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-33.0%
Peak to trough
Max drawdown 5Y
-65.3%
Peak to trough
ATR 14
0.25
5.47% of price
Beta (reported)
0.20
5Y monthly, from filing
Short interest
Shares short
43.34M
Prior 38.51M
Change vs prior
+12.6%
Shorts adding
% of float
24.66%
Heavily shorted
% of shares out
21.10%
Against total outstanding
Days to cover
29.3
Crowded exit
Float
129.75M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 18, 25 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Nov 14, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Nov 13, 25 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Oct 23, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Sep 9, 25 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 8, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Sep 3, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 15, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Aug 15, 25 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
| Jun 1, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| May 29, 25 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay dateApr 28, 2017
Last split—
Split date—
SEC filings
Offering Registrations
S-8 · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-06-08
Periodic Financial Reports
10-Q · 2026-05-12
Proxy Statements
DEF 14A · 2026-04-24
Proxy Statements
PRE 14A · 2026-04-10
Corporate Changes & Voting Matters
8-K · 2026-03-13
Corporate Changes & Voting Matters
8-K · 2026-01-27
Corporate Changes & Voting Matters
8-K · 2026-01-09
Headlines
Top Premarket Gainers
MT Newswires · 22h ago
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Business Wire · 44d ago
Savara Announces New Employment Inducement Grant
Business Wire · 48d ago
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire · 57d ago
What Insmed Stock's Premium Is Actually Buying
Trefis · 61d ago
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
Business Wire · 69d ago
Here's Why You Should Add Savara Stock to Your Portfolio Now
Zacks · 77d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.